Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Dexcom Inc. Revenue & Financial Statements
Dexcom Inc. reported revenue of $4.7B for the fiscal year ended December 31, 2025, up 15.6% year over year, with net income of $836.3M and diluted EPS of $2.09.
- Company
- Dexcom Inc. DXCM · NASDAQ
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 2.4B | 2.9B | 3.6B | 4.0B | 4.7B |
| Cost of revenue | 768.0M | 1.0B | 1.3B | 1.6B | 1.9B |
| Gross profit | 1.7B | 1.9B | 2.3B | 2.4B | 2.8B |
| Operating income | 265.8M | 391.2M | 597.7M | 600.0M | 911.8M |
| Pretax income | (61.4M) | (72.7M) | (22.0M) | 49.2M | 127.0M |
| Net income | 152.0M | 329.1M | 536.4M | 584.9M | 836.3M |
| Diluted EPS | 1.55 | 0.82 | 1.30 | 1.42 | 2.09 |
| EBITDA | 367.8M | 547.1M | 783.7M | 817.7M | 1.2B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 921.0M | 1.0B | 994.2M | 1.1B | 1.0B | 1.2B | 1.2B | 1.3B |
| Cost of revenue | 359.1M | 377.6M | 400.4M | 457.7M | 447.0M | 468.3M | 477.9M | 466.9M |
| Gross profit | 561.9M | 626.7M | 593.8M | 655.8M | 589.0M | 688.8M | 731.4M | 792.7M |
| Operating income | 101.1M | 158.0M | 152.0M | 188.9M | 133.7M | 212.6M | 242.5M | 323.0M |
| Pretax income | 132.5M | 187.8M | 177.4M | 211.3M | 154.3M | 241.1M | 352.3M | 340.7M |
| Net income | 125.8M | 142.8M | 236.0M | 80.3M | 115.6M | 261.2M | 281.7M | 267.3M |
| Diluted EPS | 0.36 | 0.35 | 0.34 | 0.38 | 0.27 | 0.45 | 0.70 | 0.67 |
| EBITDA | 153.6M | — | 207.3M | 246.7M | 193.7M | 275.6M | 306.1M | 388.2M |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 4.9B | 5.4B | 6.3B | 6.5B | 6.3B |
| Current assets | 3.7B | 3.7B | 4.4B | 4.3B | 4.0B |
| Cash & equivalents | 1.1B | 642.3M | 566.3M | 606.1M | 917.7M |
| Total liabilities | 2.6B | 3.3B | 4.2B | 4.4B | 3.6B |
| Current liabilities | 720.8M | 1.8B | 1.6B | 2.9B | 2.1B |
| Long-term debt | — | — | — | — | — |
| Total debt | — | — | — | — | — |
| Stockholders’ equity | 2.3B | 2.1B | 2.1B | 2.1B | 2.7B |
| Net debt | — | — | — | — | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 442.5M | 669.5M | 748.5M | 989.5M | 1.4B |
| Investing cash flow | (216.1M) | (521.5M) | (507.2M) | (207.5M) | 536.0M |
| Financing cash flow | 10.4M | (552.5M) | (318.6M) | (734.8M) | (1.7B) |
| Capital expenditure | 389.2M | 364.8M | 236.6M | 358.8M | 363.5M |
| Free cash flow | 53.3M | 304.7M | 511.9M | 630.7M | 1.1B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 113.4M | 126.5M | 150.8M | 170.4M | 159.6M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every DXCM filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.